Global Diabetes Clinical Trials Market Size, Share, Trends And Forecast, 2026-2033 AI And Decentralized Trials Drive Growth To USD 9.3 Billion At 7.9% CAGR


Date:

(MENAFN- GlobeNewsWire - Nasdaq) Decentralized and hybrid trials, digital monitoring, AI, precision medicine and emerging markets can cut costs, improve recruitment and accelerate time-to-market.

Dublin, Nov. 20, 2026 (GLOBE NEWSWIRE) -- "Diabetes Clinical Trials Market Size, Share & Trends Analysis Report by Phase, Study Design, Indication, Indication by Study Design, Service, Sponsor, Region, and Segment Forecasts, 2026-2033" has been added to ResearchAndMarkets.com's offering.

The global diabetes clinical trials market was valued at an estimated USD 5.1 billion in 2025 and is projected to reach USD 9.3 billion by 2033, expanding at a compound annual growth rate of 7.9% from 2026 to 2033. Market growth is supported by the increasing prevalence of diabetes, a rising incidence of related complications, broader clinical research activity, and higher R&D investment from pharmaceutical and biotechnology companies.

An aging global population, sedentary lifestyles, and changing dietary habits are contributing to the growing need for innovative diabetes treatments. In response, sponsors are investing in clinical research focused on improving glycemic control, reducing complications, and delivering stronger long-term patient outcomes. Demand is particularly strong for personalized medicine, combination therapies, long-acting insulin formulations, and treatments designed to address cardiovascular and renal comorbidities.

The diabetes clinical trials market is also benefiting from the adoption of patient-centric research strategies. Decentralized and hybrid clinical trial models are helping sponsors expand access, improve patient recruitment and retention, and streamline study execution. Wearable glucose monitors, continuous glucose monitoring systems, and remote patient monitoring platforms are increasing data accuracy while enabling researchers to collect information beyond traditional clinical sites.

Artificial intelligence, big data analytics, and real-world evidence are expected to play increasingly important roles in trial design, patient selection, protocol optimization, and data analysis. These technologies can help sponsors identify appropriate study populations, monitor safety signals, and accelerate decision-making throughout the clinical development process. Emerging markets are also attracting greater clinical trial activity because of their diverse patient populations and cost-effectiveness.

Innovation across the diabetes treatment landscape is creating additional opportunities for clinical research organizations, pharmaceutical companies, biotechnology developers, medical device manufacturers, and supporting service providers. Continuous glucose monitoring, closed-loop insulin delivery systems, GLP-1 receptor agonists, and SGLT2 inhibitors continue to influence treatment strategies and clinical pipelines. Companies are also pursuing collaborations, partnerships, and mergers to strengthen development capabilities, expand geographic reach, optimize trial protocols, and reduce time-to-market.

Regulatory support and increased industry funding are further encouraging diabetes clinical trial expansion. As precision medicine becomes more prominent, sponsors are focusing on therapies tailored to specific patient characteristics, disease profiles, and risk factors. This shift is expected to improve study efficiency and support the development of treatments that address both diabetes and its associated complications.

Report Segmentation

The report analyzes revenue growth at the regional and country levels and evaluates industry trends across market sub-segments from 2021 to 2033. The analysis covers phase, study design, indication, indication by study design, service, sponsor, and region.

  • Phase: Phase I, Phase II, Phase III, and Phase IV.
  • Study design: Interventional trials, observational trials, and expanded access trials.
  • Indication: Type 1 Diabetes Mellitus (T1DM), Type 2 Diabetes Mellitus (T2DM), gestational diabetes, and other indications.
  • Indication by study design: Interventional, observational, and expanded access trials across Type 1 Diabetes Mellitus (T1DM), Type 2 Diabetes Mellitus (T2DM), gestational diabetes, and other indications.
  • Service: Protocol designing, site identification, patient recruitment, laboratory services, analytical testing services, clinical trial data management services, and other supporting services.
  • Sponsor: Pharmaceutical & biopharmaceutical companies, medical device companies, and other sponsors.

Regional Coverage

  • North America: U.S., Canada, and Mexico.
  • Europe: UK, Germany, France, Italy, Spain, Denmark, Sweden, and Norway.
  • Asia Pacific: China, Japan, India, Australia, South Korea, and Thailand.
  • Latin America: Brazil, Argentina, and Colombia.
  • Middle East and Africa (MEA): South Africa, UAE, Saudi Arabia, Kuwait, Qatar, and Oman.

With diabetes prevalence continuing to rise worldwide, the market is positioned for sustained expansion through 2033. Technological innovation, evolving treatment approaches, diversified trial locations, and stronger collaboration among industry participants are expected to accelerate clinical development and create new opportunities across the global diabetes research ecosystem.

Key Attributes:

Report Attribute Details
No. of Pages 150
Forecast Period 2025 - 2033
Estimated Market Value (USD) in 2025 $5.1 Billion
Forecasted Market Value (USD) by 2033 $9.3 Billion
Compound Annual Growth Rate 7.9%
Regions Covered Global


Key Topics Covered:

Chapter 1. Research Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Phase
1.2.2. Study Design
1.2.3. Indication
1.2.4. Indication by Study Design
1.2.5. Service
1.2.6. Sponsor
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased Database
1.4.2. Internal Database
1.4.3. Secondary Sources
1.4.4. Primary Research
1.5. Information Or Data Analysis
1.5.1. Data Analysis Models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity Flow Analysis
1.7.2. Top-Down Analysis
1.7.3. Botton-Up Approach
1.7.4. Multivariate Analysis
1.8. List Of Secondary Sources
1.9. List Of Abbreviations
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Diabetes Clinical Trials Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Increasing Research and Development Activities
3.2.1.2. Adoption of New Technology in Clinical Research
3.2.1.3. Increasing Prevalence of Chronic Diseases
3.2.1.4. Globalization of Clinical Trials
3.2.1.5. Shift Toward Personalized Medicine
3.2.2. Market Restraint Analysis
3.2.2.1. Stringent Regulations in New Drug Development
3.2.2.2. Lack of Skilled Workforce in Clinical Research
3.3. Technology Landscape
3.4. Pricing Model Analysis
3.5. Tariff Impact Analysis
3.6. Value Chain Analysis
3.6.1. Supply Trends
3.6.2. Demand Trends
3.7. Market Analysis Tools
3.7.1. Porter's Five Forces Analysis
3.7.2. PESTEL by SWOT Analysis
Chapter 4. Diabetes Clinical Trials Market: Phase Estimates & Trend Analysis
4.1. Diabetes Clinical Trials Market, By Phase: Segment Dashboard
4.2. Diabetes Clinical Trials Market, By Phase: Movement Analysis
4.3. Diabetes Clinical Trials Market Estimates & Forecasts, By Phase, 2021 - 2033 (USD Million)
4.4. Phase I
4.4.1. Phase I Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.5. Phase II
4.5.1. Phase II Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.6. Phase III
4.6.1. Phase III Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.7. Phase IV
4.7.1. Phase IV Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 5. Diabetes Clinical Trials Market: Study Design Estimates & Trend Analysis
5.1. Diabetes Clinical Trials Market, By Study Design: Segment Dashboard
5.2. Diabetes Clinical Trials Market, By Study Design: Movement Analysis
5.3. Diabetes Clinical Trials Market Estimates & Forecasts, By Study Design, 2021 - 2033 (USD Million)
5.4. Interventional Trials
5.4.1. Interventional Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.5. Observational Trials
5.5.1. Observational Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.6. Expanded Access Trials
5.6.1. Expanded Access Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 6. Diabetes Clinical Trials Market: Indication Estimates & Trend Analysis
6.1. Diabetes Clinical Trials Market, By Indication: Segment Dashboard
6.2. Diabetes Clinical Trials Market, By Indication: Movement Analysis
6.3. Diabetes Clinical Trials Market Estimates & Forecasts, By Indication, 2021 - 2033 (USD Million)
6.4. Type 1 Diabetes Mellitus (T1DM)
6.4.1. Type 1 Diabetes Mellitus (T1DM) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5. Type 2 Diabetes Mellitus (T2DM)
6.5.1. Type 2 Diabetes Mellitus (T2DM) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.6. Gestational Diabetes
6.6.1. Gestational Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.7. Others
6.7.1. Others Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 7. Diabetes Clinical Trials Market: Indication by Study Design Estimates & Trend Analysis
7.1. Diabetes Clinical Trials Market, By Indication by Study Design: Segment Dashboard
7.2. Diabetes Clinical Trials Market, By Indication by Study Design: Movement Analysis
7.3. Diabetes Clinical Trials Market Estimates & Forecasts, By Indication by Study Design, 2021 - 2033 (USD Million)
7.4. Analysis Framework: Each indication includes overall market estimates and forecasts and separate estimates and forecasts for Interventional Trials, Observational Trials, and Expanded Access Trials, 2021 - 2033 (USD Million)
7.5. Type 1 Diabetes Mellitus (T1DM)
7.6. Type 2 Diabetes Mellitus (T2DM)
7.7. Gestational Diabetes
7.8. Others
Chapter 8. Diabetes Clinical Trials Market: Service Estimates & Trend Analysis
8.1. Diabetes Clinical Trials Market, By Service: Segment Dashboard
8.2. Diabetes Clinical Trials Market, By Service: Movement Analysis
8.3. Diabetes Clinical Trials Market Estimates & Forecasts, By Service, 2021 - 2033 (USD Million)
8.4. Protocol Designing
8.4.1. Protocol Designing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5. Site Identification
8.5.1. Site Identification Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.6. Patient Recruitment
8.6.1. Patient Recruitment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.7. Laboratory Services
8.7.1. Laboratory Services Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.8. Analytical Testing Services
8.8.1. Analytical Testing Services Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.9. Clinical Trial Data Management Services
8.9.1. Clinical Trial Data Management Services Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.10. Others
8.10.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 9. Diabetes Clinical Trials Market: Sponsor Estimates & Trend Analysis
9.1. Diabetes Clinical Trials Market, By Sponsor: Segment Dashboard
9.2. Diabetes Clinical Trials Market, By Sponsor: Movement Analysis
9.3. Diabetes Clinical Trials Market Estimates & Forecasts, By Sponsor, 2021 - 2033 (USD Million)
9.4. Pharmaceutical & Biopharmaceutical Companies
9.4.1. Pharmaceutical & Biopharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
9.5. Medical Device Companies
9.5.1. Medical Device Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
9.6. Others
9.6.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 10. Diabetes Clinical Trials Market: Regional Estimates & Trend Analysis
10.1. Regional Market Dashboard
10.2. Regional Market Share Analysis, 2025 & 2033
10.3. Country Analysis Framework: Each listed country includes Key Country Dynamics, Competitive Scenario, Regulatory Framework, and Market Estimates and Forecasts, 2021 - 2033 (USD Million)
10.4. North America
10.4.1. North America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
10.4.2. U.S.
10.4.3. Canada
10.4.4. Mexico
10.5. Europe
10.5.1. Europe Market Estimates and Forecasts, 2021 - 2033 (USD Million)
10.5.2. UK
10.5.3. Germany
10.5.4. France
10.5.5. Italy
10.5.6. Spain
10.5.7. Denmark
10.5.8. Sweden
10.5.9. Norway
10.6. Asia Pacific
10.6.1. Asia Pacific Market Estimates and Forecasts, 2021 - 2033 (USD Million)
10.6.2. Japan
10.6.3. China
10.6.4. India
10.6.5. Australia
10.6.6. Thailand
10.6.7. South Korea
10.7. Latin America
10.7.1. Latin America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
10.7.2. Brazil
10.7.3. Argentina
10.7.4. Colombia
10.8. MEA
10.8.1. MEA Market Estimates and Forecasts, 2021 - 2033 (USD Million)
10.8.2. South Africa
10.8.3. UAE
10.8.4. Saudi Arabia
10.8.5. Kuwait
10.8.6. Qatar
10.8.7. Oman
Chapter 11. Competitive Landscape
11.1. Key Participant Categorization
11.1.1. Market Leaders
11.1.2. Emerging Players
11.2. Market Assessment Analysis, 2025 (Heat Map Analysis)
11.3. Company Profile Framework: Each company profile includes Company Overview, Financial Performance, Service Benchmarking, and Strategic Initiatives
11.4. Company Profiles
11.4.1. Syneos Health
11.4.2. Medpace
11.4.3. IQVIA
11.4.4. ICON plc
11.4.5. Fortrea
11.4.6. Parexel
11.4.7. ProSciento
11.4.8. Profil Institut fur Stoffwechselforschung
11.4.9. Novo Nordisk
11.4.10. Eli Lilly and Company
11.4.11. Sanofi
11.4.12. AstraZeneca
List of Tables [199]
List of Figures [124]

Companies Featured

  • Syneos Health
  • Medpace
  • IQVIA
  • ICON plc
  • Fortrea
  • Parexel
  • ProSciento
  • Profil Institut fur Stoffwechselforschung
  • Novo Nordisk
  • Eli Lilly and Company
  • Sanofi
  • AstraZeneca

For more information about this report visit

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN20112026004107003653ID1111996989


GlobeNewsWire - Nasdaq

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.



More Story

Search